Portfolio News Venatorx Pharmaceuticals

Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam

By WebmasterFebruary 23, 2024December 12th, 2024No Comments

Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam

No Clinical Safety or Efficacy Issues Identified

No Requirement for Further Clinical Data or Trials

Previous PostVittoria Therapeutics Announces Appointment of Life Sciences Veteran Rosemary Mazanet, M.D., Ph.D. as Chief Medical Officer
Next PostNew England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection